Long-Term Effects of COVID-19 on Chronic Obstructive Pulmonary Disease.

IF 3.1 3区 医学 Q2 RESPIRATORY SYSTEM
Chi-Tai Lee, Ping-Huai Wang, Shih-Lung Cheng
{"title":"Long-Term Effects of COVID-19 on Chronic Obstructive Pulmonary Disease.","authors":"Chi-Tai Lee, Ping-Huai Wang, Shih-Lung Cheng","doi":"10.2147/COPD.S523149","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Research has demonstrated that chronic obstructive pulmonary disease (COPD) is a negative prognostic factor for patients with the coronavirus disease 2019 (COVID-19). The long-term complications of COVID-19 among patients with COPD remain poorly understood due to limited studies.</p><p><strong>Methods: </strong>This retrospective study included patients with COPD who underwent regular follow-ups in a medical center between January 1, 2020, and December 31, 2022. The patients were categorized into COVID-19 and non-COVID-19 groups. Comparative analyses were conducted to assess clinical demographics, characteristics, acute exacerbations of COPD (AECOPD), and survival rates between the two groups. Subgroup analysis was performed based on inpatient and outpatient status within the COVID-19 group.</p><p><strong>Results: </strong>Of the 696 patients with COPD, 86 (12.4%) were included in the COVID-19 group, while 610 (87.6%) were included in the non-COVID-19 group. Patients in the COVID-19 group were significantly older (age: 75.0 ± 8.8 years versus 72.0 ± 9.0 years, <i>p</i> = 0.004), exhibited higher mortality rates (4.6% versus 0%, <i>p</i> < 0.001), and increased annual times of AECOPD (0.17 versus 0.08, <i>p</i> = 0.018) than those in the non-COVID-19 group after COVID-19. Multivariate analysis revealed that COVID-19 infection is an independent risk factor for increased AECOPD incidence (adjusted odds ratio: 1.74; 95% confidence interval [CI]: 1.07-2.83, <i>p</i> = 0.024). Within the COVID-19 group, the inpatient subgroup exhibited a higher prevalence of heart failure comorbidity (20% versus 2.8%, <i>p</i> = 0.035) and lower forced vital capacity than the outpatient subgroup (2.03 ± 0.60 L versus 2.56 ± 0.72 L, <i>p</i> = 0.016).</p><p><strong>Conclusion: </strong>Age is a significant risk factor for COVID-19 infection among patients with COPD. After COVID-19, these patients exhibit an increased frequency of severe exacerbations and a high risk of mortality. Notably, the susceptibility to severe exacerbations persists regardless of whether the patients receive inpatient or outpatient care.</p>","PeriodicalId":48818,"journal":{"name":"International Journal of Chronic Obstructive Pulmonary Disease","volume":"20 ","pages":"2539-2548"},"PeriodicalIF":3.1000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12282603/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Chronic Obstructive Pulmonary Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/COPD.S523149","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Research has demonstrated that chronic obstructive pulmonary disease (COPD) is a negative prognostic factor for patients with the coronavirus disease 2019 (COVID-19). The long-term complications of COVID-19 among patients with COPD remain poorly understood due to limited studies.

Methods: This retrospective study included patients with COPD who underwent regular follow-ups in a medical center between January 1, 2020, and December 31, 2022. The patients were categorized into COVID-19 and non-COVID-19 groups. Comparative analyses were conducted to assess clinical demographics, characteristics, acute exacerbations of COPD (AECOPD), and survival rates between the two groups. Subgroup analysis was performed based on inpatient and outpatient status within the COVID-19 group.

Results: Of the 696 patients with COPD, 86 (12.4%) were included in the COVID-19 group, while 610 (87.6%) were included in the non-COVID-19 group. Patients in the COVID-19 group were significantly older (age: 75.0 ± 8.8 years versus 72.0 ± 9.0 years, p = 0.004), exhibited higher mortality rates (4.6% versus 0%, p < 0.001), and increased annual times of AECOPD (0.17 versus 0.08, p = 0.018) than those in the non-COVID-19 group after COVID-19. Multivariate analysis revealed that COVID-19 infection is an independent risk factor for increased AECOPD incidence (adjusted odds ratio: 1.74; 95% confidence interval [CI]: 1.07-2.83, p = 0.024). Within the COVID-19 group, the inpatient subgroup exhibited a higher prevalence of heart failure comorbidity (20% versus 2.8%, p = 0.035) and lower forced vital capacity than the outpatient subgroup (2.03 ± 0.60 L versus 2.56 ± 0.72 L, p = 0.016).

Conclusion: Age is a significant risk factor for COVID-19 infection among patients with COPD. After COVID-19, these patients exhibit an increased frequency of severe exacerbations and a high risk of mortality. Notably, the susceptibility to severe exacerbations persists regardless of whether the patients receive inpatient or outpatient care.

COVID-19对慢性阻塞性肺疾病的长期影响
背景:研究表明,慢性阻塞性肺疾病(COPD)是2019冠状病毒病(COVID-19)患者预后的负面因素。由于研究有限,COVID-19在COPD患者中的长期并发症仍然知之甚少。方法:本回顾性研究纳入了2020年1月1日至2022年12月31日期间在某医疗中心接受定期随访的COPD患者。将患者分为新冠肺炎组和非新冠肺炎组。比较分析两组患者的临床人口学特征、慢性阻塞性肺病急性加重(AECOPD)和生存率。根据COVID-19组的住院和门诊情况进行亚组分析。结果:696例COPD患者中,新冠肺炎组86例(12.4%),非新冠肺炎组610例(87.6%)。COVID-19组患者的年龄明显高于非COVID-19组(75.0±8.8岁比72.0±9.0岁,p = 0.004),死亡率明显高于非COVID-19组(4.6%比0%,p < 0.001),年AECOPD次数明显高于非COVID-19组(0.17比0.08,p = 0.018)。多因素分析显示,COVID-19感染是AECOPD发病率增加的独立危险因素(校正优势比:1.74;95%可信区间[CI]: 1.07-2.83, p = 0.024)。在COVID-19组中,住院亚组的心力衰竭合并症发生率高于门诊亚组(20%比2.8%,p = 0.035),强迫肺活量低于门诊亚组(2.03±0.60 L比2.56±0.72 L, p = 0.016)。结论:年龄是COPD患者COVID-19感染的重要危险因素。在COVID-19之后,这些患者出现严重恶化的频率增加,死亡风险高。值得注意的是,对严重恶化的易感性持续存在,无论患者是否接受住院或门诊治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.80
自引率
10.70%
发文量
372
审稿时长
16 weeks
期刊介绍: An international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus will be given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols. This journal is directed at specialists and healthcare professionals
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信